Compass Therapeutics, Inc.
Financials
Valuation Metrics
Compass Therapeutics, Inc.'s Market Cap is $342M. At end of 2025 it was $993M. Ranked #2919 of 3,121 in US market (top 94%), #1311 of 1,463 on NASDAQ (top 90%), #239 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $342M | US#2,919/3,121 Sec#239/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-73M | US—/3,121 Sec—/266 |
| Total Assets | $190M | US#3,005/3,121 Sec#250/266 |
| Net Assets | $166M | US#2,729/3,121 Sec#201/266 |
| Employees | 39 | US#2,738/3,121 Sec#216/266 |
| Value | ||
| P/B | 2.06x | US#1,253/3,121 Sec#51/266 |
| FCF Yield | -16.09% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -44.23% | US#2,655/3,121 Sec#146/266 |
| ROA | -38.62% | US#2,941/3,121 Sec#186/266 |
| Financial Health | ||
| Debt Ratio | 14.53% | US#170/3,121 Sec#68/266 |
| Total Debt | $10M | US#2,839/3,121 Sec#200/266 |
| FCF | $-55M | US#2,535/3,121 Sec#117/266 |
| Cash | $35M | US#2,716/3,121 Sec#244/266 |
| Current Ratio | 11.22x | US#225/3,121 Sec#70/266 |
| Performance | ||
| 1Y Return | -48.37% | US#2,884/3,121 Sec#243/266 |
| 1M Return | -23.39% | US#3,010/3,121 Sec#247/266 |
| From 52W High | -72.38% | US#3,041/3,121 Sec#249/266 |
| 1Y MDD | -75.04% | US#3,018/3,121 Sec#246/266 |
| Trading | ||
| Volume | 6,982,359 shares | US#700/3,121 Sec#69/266 |
| Trading Value | $13M | US#2,687/3,121 Sec#225/266 |
| Per Share | ||
| EPS | $-0.41 | US—/3,121 Sec—/266 |
| BPS | $0.92 | US#2,713/3,121 Sec#207/266 |
Company Info
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.